Therapeutic synergy of Triptolide and MDM2 inhibitor against acute myeloid leukemia through modulation of p53-dependent and -independent pathways

Therapeutic synergy of Triptolide and MDM2 inhibitor against acute myeloid leukemia through modulation of p53-dependent and -independent pathways

Abstract Dysregulation of MDM2, a p53 negative regulator, frequently occurs in acute myeloid leukemia (AML) and is associated with unfavorable prognoses, rendering the p53-MDM2 axis an attractive target for the development of small-molecule inhibitors. MDM2 antagonists have been intensely developed...

Full description

Bibliographic Details
Main Authors: Qinwei Chen, Suqi Deng, Manman Deng, Yuanfei Shi, Mengya Zhong, Lihong Ding, Yuelong Jiang, Yong Zhou, Bing Z. Carter, Bing Xu
Format: Article
Language:English
Published: BMC 2022-04-01
Series:Experimental Hematology & Oncology
Subjects:
Acute myeloid leukemia (AML)
p53
MDM2 inhibitor
Triptolide
MYC
ATF4
Online Access:https://doi.org/10.1186/s40164-022-00276-z

Internet

https://doi.org/10.1186/s40164-022-00276-z

Similar Items